Navigation Links
Lightlake Therapeutics Retains KCSA Strategic Communications as Corporate Communications Advisors
Date:8/5/2013

LONDON, Aug. 5, 2013 /PRNewswire/ -- Lightlake Therapeutics Inc., ("Lightlake" or the "Company") (OTC BB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that it has retained KCSA Strategic Communications ("KCSA"), a leading New York-based communications firm, to direct the Company's investor and public relations programs.

KCSA will deploy an integrated investor and public relations campaign to increase awareness of Lightlake and its treatments for Binge Eating Disorder ("BED"), for Bulimia Nervosa ("BN"), and for the complications of drug addiction. The campaign will focus on the various influencers in the healthcare sector, in addition to outreach to business and key trade publications.

KCSA has garnered a strong reputation through four decades of experience representing domestic and international companies across all industries, including healthcare services and biopharmaceuticals. Managing Partners Todd Fromer and Lewis Goldberg will head up the account and provide strategic guidance on financial and media communication.

"We understand the importance of a proactive communications program to effectively reach the investment community, our shareholders, and the appropriate media. As we continue to grow our business and develop modern treatments for addiction diseases, we look forward to working closely with KCSA to effectively communicate our growth potential. We have exciting treatments in our pipeline that are in advanced stage clinical trials, providing us with significant short-term and long-term opportunities that can act as catalysts for our business. With KCSA's guidance, we hope to highlight the ongoing development of these treatments to our shareholders and the potential value they could have upon receiving regulatory market clearance," said Dr. Roger Crystal, Chief Executive Officer of Lightlake.

"We believe our experience with other biopharmaceutical companies and subsequent success with providing an integrated communications platform makes KCSA uniquely qualified to communicate Lightlake's growth potential," said Mr. Fromer. "Addiction affects millions of people and their families in the United States alone, and we are enthusiastic about increasing awareness of Lightlake and its treatment pipeline."

To be added to the Lightlake Therapeutics investor email list, please email pcarlson@kcsa.com with LLTP in the subject line.

About Lightlake Therapeutics
Lightlake Therapeutics Inc., a London-based biopharmaceutical company, is using its expertise in opioid antagonists to build a platform of innovative solutions to common addictions and related disorders. The Company holds patents covering the use of intranasal naloxone to treat Binge Eating Disorder ("BED") as well as patents covering addiction to drugs including cocaine, amphetamine, and MDMA. Lightlake is currently focused on advancing its treatment for BED, which has successfully completed Phase II clinical trials, and a Phase II trial is planned for the indication of Bulimia Nervosa. Lightlake is also applying its technology to develop a treatment for managing the complications of opioid drug addiction in collaboration with the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health. For more information please visit: http://www.lightlaketherapeutics.com

About KCSA Strategic Communications
KCSA is a fully-integrated communications agency specializing in public relations, investor relations and marketing with expertise in financial and professional services, technology, healthcare, media, energy and public services companies. Since 1969, the firm has demonstrated strategic thinking and program execution that drives results for its clients in the ever-changing communications and digital landscape. The firm's clients are its best references. For more information, please visit www.kcsa.com.

Investor Relations Contact:
Phil Carlson / Josh Dver
KCSA Strategic Communications
212-896-1233 / 212-896-1239 
pcarlson@kcsa.com / jdver@kcsa.com

Public Relations Contact:
Anne Donohoe / Taylor McGrann
KCSA Strategic Communications
212-896-1261 / 212-896-1253 
adonohoe@kcsa.com / tmcgrann@kcsa.com


'/>"/>
SOURCE Lightlake Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. PTC Therapeutics To Host Second Quarter 2013 Financial Results Conference Call And Webcast
2. Cell Therapeutics Reports Second Quarter 2013 Financial Results
3. AuraSense Therapeutics Closes Tranche II of Series B Equity Investment
4. Covington Advises Actelion in Acquisition of Ceptaris Therapeutics
5. Oncos Therapeutics Granted Orphan Drug Designation for CGTG-102 in Soft Tissue Sarcoma (STS) by FDA and EMA
6. Diabetes Therapeutics Market in India to 2018 - Rapid Uptake of DPP-IV Inhibitors, GLP-1 Agonists and Expanding Insulin Segment to Drive Growth
7. Serina Therapeutics Announces Agreement with the Scripps Research Institute for Development of Polymer-Antibody Drug Conjugates
8. Advanced Prenatal Therapeutics Appoints Dr. Nihar Nayak to its Scientific Advisory Board
9. Signature Therapeutics Receives BrIDGs Award to Advance Its Abuse-Deterrent Oxycodone, PF614
10. Orexigen Therapeutics to Host Second Quarter 2013 Financial Results Conference Call and Webcast
11. Intarcia Therapeutics Appoints Gino Santini To Its Board Of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Market - Forecast to 2022" report to their offering. ... method for the patients with kidney failure, it replaces the ... from the patient,s blood and thus the treatment helps to ... chloride in balance. Increasing number of ESRD ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... 2016 Bracket , a leading clinical trial ... clinical outcomes platform, Bracket eCOA (SM) 6.0, at the ... – 30, 2016 in Philadelphia , Pennsylvania.  ... Assessment product of its kind to fully integrate with RTSM, ... eCOA 6.0 is a flexible platform for electronic clinical outcomes ...
Breaking Medicine Technology:
(Date:6/27/2016)... , ... June 27, 2016 , ... "FCPX editors can ... inside of Final Cut Pro X," said Christina Austin - CEO of Pixel Film ... Final Cut Pro X users can now reveal the media of their ...
(Date:6/27/2016)... , ... June 27, 2016 , ... ... edge technology to revolutionize the emergency ambulance transport experience for the millions of ... of how Uber has disrupted the taxi industry through the use of technology. ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, ... Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility ... home to some of the world’s leading providers of cereal and other breakfast foods. ...
(Date:6/26/2016)... ... ... Kasmer, a legally blind and certified personal trainer is helping to develop a weight loss ... plans to fix the two major problems leading the fitness industry today:, ... , They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... ... 2016 , ... Austin residents seeking Mohs surgery services, can now turn to ... Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to ... fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of ...
Breaking Medicine News(10 mins):